Derick Lau
Department of Internal Medicine
University of California
Davis Cancer Center
Sacramento
USA
Name/email consistency: high
- Population-based phase I trial of irinotecan and epirubicin. Lau, D., Johl, J., Huynh, M., Davies, A., Tanaka, M., Lara, P., Gandara, D. Am. J. Clin. Oncol. (2008)
- Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. Lau, D., Guo, L., Liu, R., Marik, J., Lam, K. Lung. Cancer (2006)
- Computer-assisted image analysis of bronchioloalveolar carcinoma. Lau, D., Seibert, A., Gandara, D., Laptalo, L., Geraghty, E., Coulon, C. Clin. Lung. Cancer (2005)
- Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?. Lau, D., Guo, L., Gandara, D., Young, L.J., Xue, L. Anticancer. Drugs (2004)
- Expression and regulation of a molecular marker, SPR1, in multistep bronchial carcinogenesis. Lau, D., Xue, L., Hu, R., Liaw, T., Wu, R., Reddy, S. Am. J. Respir. Cell Mol. Biol. (2000)
- Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Lau, D.H., Xue, L., Young, L.J., Burke, P.A., Cheung, A.T. Cancer Biother. Radiopharm. (1999)